ICDs (implantable cardioverter defibrillators) give Medtronic earnings boost at start of FY2005
This article was originally published in Clinica
Boasting 31% growth in sales for the first quarter, Medtronic's implantable cardioverter defibrillator (ICD) business got off to an auspicious start for fiscal 2005. Despite shortfalls in the company's other businesses, the star performance by its ICD franchise pulled the group's quarterly net earnings up to $529.7m - an 18% increase from the first quarter last year - and enabled the company to meet analysts' estimates.
You may also be interested in...
Siemens Healthineers' product mix of diagnostics and imaging products meant it was in the middle of a very dynamic situation when COVID-19 struck.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.